Immunotherapy combos could provide a new path forward for troubled cancer vaccine field
When Johan Vansteenkiste of Belgium University Hospitals Leuven reported the full results of GlaxoSmithKline's ($GSK) MAGE-A3 failure at the European Society of Medical Oncology's annual congress last weekend, he wasn't the first to outline a cancer vaccine flop. But he did offer a way out from under the dark cloud hanging over the field, and it's one that some cancer vaccine makers are already embracing.
"For future progress, I think a combination of vaccination and checkpoint inhibition may be of major interest," he told the ESMO group in Madrid, as quoted by Reuters.
Without checkpoint inhibitors, cancer vaccines--intended to stimulate the immune system--have successfully triggered immune responses, but that hasn't stopped cancer cells from escaping undetected, the news service notes.
But with checkpoint inhibitors, designed to prevent tumor cells from slipping away unnoticed, they may be able to do just that. "You have this really complementary biologic approach," David Reese, Amgen's VP of translational sciences, told FierceVaccines in June.
Some vaccinemakers have already caught on to the potential of immunotherapy combos. Amgen ($AMGN) is testing its melanoma fighter, T-Vec, in conjunction with Keytruda. And New Jersey biotech Advaxis ($ADXS), too, struck an August agreement to test its vaccine alongside the Merck drug.
And it's not just vaccinemakers who are seeking out combo partners. Last month, Severin Schwan, CEO of cancer giant Roche ($RHHBY), said his company was exploring ways of coupling its own checkpoint inhibitors with vaccines that had missed the mark when given on their own, Reuters notes.
- see Reuters' take
Special Report: ASCO preview: What's the outlook for cancer vaccines?
Merck KGaA calls it quits on cancer vaccine--again
Advaxis teams up with Merck to test its vaccine in prostate cancer
Aduro nabs FDA 'breakthrough' nod for pancreatic cancer vaccine combo
Amgen to pursue T-Vec approval despite PhIII survival miss
GlaxoSmithKline admits defeat in PhIII cancer vaccine trial